US Stock Market Movement: Praxis surges on October 19 as brokers turn bullish and neuropharmaceutical development progresses

Praxis October 19 Surge Analysis

Keywords: Broker bullish outlook, neurological drug development

1. On October 16, JPMorgan initiated coverage of Praxis for the first time, giving it an “Overweight” rating with a target price of $700.

2. On October 15, UBS initiated coverage of Praxis for the first time, giving it a “Buy” rating with a target price of $706.

(Disclaimer: This content is summarized from publicly available information by AI technology and is for reference only. It does not constitute investment advice.)